Perifosine: Updated Phase II data

Updated data from a double-blind, placebo-controlled, U.S. Phase II trial in 35 evaluable patients showed that 50 mg daily perifosine plus 825 mg/m 2 twice-daily Xeloda capecitabine met the primary endpoint of significantly improving median TTP vs. Xeloda alone (28 vs. 11 weeks, p=0.0012). ORR for the combination was 20% (1 complete response (CR) and 3 partial responses (PRs) vs. 7% for Xeloda alone (1 PR). Additionally, the combination produced significantly more cases of stable disease (SD) vs. Xeloda alone (15 vs. 6, p=0.036). Median OS was 18 months for perifosine plus Xeloda vs. 11 months for Xeloda alone (p=0.0136). ...